bioAffinity Technologies Announces CyPath® Lung Posters at NAVREF 2026

What Happened
bioAffinity Technologies, Inc. (BIAF) announced on September 22, 2026, that it will present two posters highlighting its noninvasive lung cancer diagnostic, CyPath® Lung, at the 2026 NAVREF Annual Conference in Arlington, Virginia. The posters focus on CyPath® Lung in clinical practice and on ongoing research evaluating the technology in veteran and military populations. The company filed a press release about the presentations as Exhibit 99.1 to its Form 8-K.

Key Details

• Filing date: September 22, 2026 (Form 8-K, Item 8.01 Other Events).
• Conference dates/location: NAVREF Annual Conference, September 27–30, 2026, Arlington, Virginia.
• Content: Two posters — one on clinical practice use of CyPath® Lung and one on research in veteran/military populations.
• Press release attached as Exhibit 99.1 to the 8-K.

Why It Matters
This 8-K signals increased visibility for CyPath® Lung through scientific and clinical engagement, especially within veteran and military health networks that could be potential adopters. The filing does not report financial results, earnings, executive changes, mergers, or other material financial disclosures. For investors, the development is a progress/visibility update rather than a statement of revenue or commercial agreements; any potential commercial or financial impact would require future announcements.